Multi-site trial evaluates the novel anti-inflammatory effects of ENV-294 in adults with moderate to severe atopic dermatitis. Overland Park, Kan.; September 16, 2025 (Business Wire) —Dr. Vince Clinical Research (DVCR), a full-service contract research organization...
New administration building opens, reinforcing DVCR’s commitment to operational excellence and a thriving team culture. OVERLAND PARK, Kan.; July 24, 2025 (Business Wire) - Dr. Vince Clinical Research (DVCR), a fast-growing contract research organization (CRO), is...
OVERLAND PARK, Kan.; January 14, 2025 (Business Wire) – Dr. Vince Clinical Research (DVCR), a contract research organization (CRO), announces the expansion of its research campus by constructing a new 5,000-square-foot administration building in Overland Park, Kansas....
OVERLAND PARK, Kan.; November 12, 2024 (Business Wire) – Dr. Vince Clinical Research (DVCR) is pleased to announce the addition of a cutting-edge clinical laboratory within the main building of its research campus. This new laboratory will significantly enhance the...
OVERLAND PARK, Kan.--(BUSINESS WIRE)--Dr. Vince Clinical Research (DVCR), a full-service contract research organization (CRO) specializing in early-phase clinical trials, is pleased to announce "Accelerating Clinical & Drug Development Timelines with AI," an...
OVERLAND PARK, Kan.—(BUSINESS WIRE)—Dr. Vince Clinical Research (DVCR), a full-service contract research organization (CRO), today announced the appointment of Sheldon Preskorn, M.D., as its Senior Vice President of Neuroscience. Dr. Preskorn is a world-renowned...
OVERLAND PARK, Kan.—(BUSINESS WIRE)—Dr. Vince Clinical Research (DVCR), a contract research organization specializing in early phase trials, announced the first dosing in a Phase II multi-center trial of SPN-820 in adults with major depressive disorder (MDD). DVCR is...
OVERLAND PARK, Kan.--(BUSINESS WIRE)--Dr. Vince Clinical Research (DVCR), a full-service Phase I-II contract research organization (CRO) announced a new solution to conduct renal and hepatic impairment studies. The solution leverages trusted relationships and more...
Dr. Vince Clinical Research (DVCR), a full-service clinical research organization (CRO), today announced the first dosing in Cingulate Therapeutics’ CTx-1301 Phase III dose-optimization onset and duration laboratory classroom study. This study is taking place in...
